Skip to nav Skip to content
  • Overview

    Cancer Focus:
    Lung Cancer, Mesothelioma, Thymoma

      Dr. Tanvetyanon is a medical oncologist with expertise in lung cancer, mesothelioma and thymic carcinoma. Services offered include a wide array of clinical trials, immunotherapy programs, and hyperthermic intraperitoneal chemotherapy (HIPEC) for malignant mesothelioma. In addition, Dr. Tanvetyanon is experienced in managing abnormal findings from lung cancer screening. Dr. Tanvetyanon is a health outcomes researcher as well as an epidemiologist. To date, he has published over 50 peer-review articles in medical journals including Journal of Clinical Oncology, Annals of Oncology, Head & Neck and Journal of Thoracic Oncology. His research is geared toward improving the quality of cancer care as well as developing of statistical model to predict survival outcomes.  

    Education & Training

    Board Certification:

    • Internal Medicine - Hematology


    • Loyola University Chicago, Stritch School of Medicine, Illinois - Medical Oncology & Hematology


    • Albert Einstein Medical Center at Thomas Jefferson Medical College, Pennsylvania -

    Medical School:

    • Chulalongkorn University in Bangkok, Thailand - MD
  • Publications

    • Saltos AN, Creelan BC, Tanvetyanon T, Chiappori AA, Antonia SJ, Shafique MR, Ugrenovic-Petrovic M, Sansil S, Neuger A, Ozakinci H, Boyle TA, Kim J, Haura EB, Gray JE. A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer. 2023 Sep.183:107313. Pubmedid: 37499521.
    • Ettinger DS, Wood DE, Stevenson J, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Otterson GA, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Shapiro TA, Singh AP, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hughes M. Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2023 Sep.21(9):961-979. Pubmedid: 37673108.
    • Gilardone S, Thapa R, Laborde J, Shafique M, Saltos A, Creelan B, Tanvetyanon T, Chiappori A, Simon G, Haura EB, Gray JE, Chen DT, Melzer D, Pellini B. Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. J Thorac Dis. 2023 Nov.15(11):6115-6125. Pubmedid: 38090314. Pmcid: PMC10713299.
    • Shields PG, Bierut L, Arenberg D, Balis D, Cinciripini PM, Davis J, Edmondson D, Feliciano J, Hitsman B, Hudmon KS, Jaklitsch MT, Leone FT, Ling P, McCarthy DE, Ong MK, Park ER, Prochaska J, Sandoval AJ, Sheffer CE, Spencer S, Studts JL, Tanvetyanon T, Tindle HA, Tong E, Triplette M, Urbanic J, Videtic G, Warner D, Whitlock CW, McCullough B, Darlow S. Smoking Cessation, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2023 Mar.21(3):297-322. Pubmedid: 36898367.
    • Singh AM, Rubiera-Pebe R, Ahmad Y, Shafique M, Hicks JK, Tanvetyanon T. Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer. JCO Oncol Pract. 2023 Jun.19(6):345-351. Pubmedid: 37075260.
    • Liveringhouse CL, Latifi K, Asous AG, Lam NB, Rosenberg SA, Dilling TJ, MacMillan GV, Chiappori AA, Haura EB, Creelan B, Gray JE, Tanvetyanon T, Shafique MR, Saltos AN, Weiner AA, Clarke J, Kelsey CR, Kim S, Caudell JJ, Rose TA, Conejo-Garcia JR, Li J, Schell MJ, Antonia SJ, Perez BA. Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023 Jul.116(4):837-848. Pubmedid: 36657497.
    • Ahmad Y, Tanvetyanon T. Amivantamab for Metastatic Lung Cancer With Paraneoplastic Disseminated Intravascular Coagulation: A Case Report. Cureus. 2023 Jan.15(1):e34033. Pubmedid: 36814728. Pmcid: PMC9940450.
    • Tanvetyanon T, Chen DT, Gray JE. Impact of COVID-19 Pandemic on Frontline Pembrolizumab-Based Treatment for Advanced Lung Cancer. J Clin Med. 2023 Feb.12(4). Pubmedid: 36836146. Pmcid: PMC9960275.
    • Cui JY, Tanvetyanon T. Iatrogenic Rupture of Saline Breast Implant Following Robotic-Assisted Lung Surgery. Cureus. 2023 Feb.15(2):e35236. Pubmedid: 36968857. Pmcid: PMC10038683.
    • Mammadova J, Tanvetyanon T. Association Between ALK Rearrangement and Ultra-Late Recurrence in Lung Cancer: Case Report and Pooled Analysis. Cureus. 2023 Dec.15(12):e51354. Pubmedid: 38292996. Pmcid: PMC10824627.
    • Dudek AZ, Xi MX, Scilla KA, Mamdani H, Creelan BC, Saltos A, Tanvetyanon T, Chiappori A. Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299. JTO Clin Res Rep. 2023 Dec.4(12):100584. Pubmedid: 38046376. Pmcid: PMC10689266.
    • Salvatori S, Tanvetyanon T. Fatal Tracheoesophageal Puncture Leakage Associated With Lenvatinib. Cureus. 2023 Aug.15(8):e43490. Pubmedid: 37719529. Pmcid: PMC10499567.
    • Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hughes M. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Ne. 2023 Apr.21(4):340-350. Pubmedid: 37015337.
    • Abdelghany K, Robinson LA, Tanvetyanon T. Impact of Robotic-Assisted Thoracic Surgery on the Completion of Adjuvant Chemotherapy Following Lung Cancer Resection. Cureus. 2022 Oct.14(10):e30364. Pubmedid: 36407249. Pmcid: PMC9665910.
    • Pevner JL, Tanvetyanon T. Prognostic Value of Positron Emission Tomography in Advanced Cholangiocarcinoma: A Single-Institution Study and Literature Review. Cureus. 2022 Nov.14(11):e31026. Pubmedid: 36475189. Pmcid: PMC9718511.
    • Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2022 May.20(5):497-530. Pubmedid: 35545176.
    • Chiappori AA, Creelan B, Tanvetyanon T, Gray JE, Haura EB, Thapa R, Barlow ML, Chen Z, Chen DT, Beg AA, Boyle TA, Castro J, Morgan L, Morris E, Aregay M, Hurtado FK, Manenti L, Antonia S. Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2022 Jun.28(11):2313-2320. Pubmedid: 35254415. Pmcid: PMC9167697.
    • Maller B, Tanvetyanon T. Emerging Approaches to Complement Low-Dose Computerized Tomography for Lung Cancer Screening: A Narrative Review. Cureus. 2022 Jul.14(7):e27309. Pubmedid: 36042989. Pmcid: PMC9410538.
    • Abdelghany K, Macaulay R, Tang Z, Tanvetyanon T. Pulmonary Ewing Sarcoma Mimicking Small Cell Lung Cancer. Clin Lung Cancer. 2022 Jul.23(5):e330-e334. Pubmedid: 35610116.
    • Maller B, Salvatori S, Tanvetyanon T. Outcomes of Intraocular Metastasis From Lung Cancer in the Era of Targeted Therapy: A Systematic Review and Pooled Analysis. Clin Lung Cancer. 2022 Dec.23(8):e519-e525. Pubmedid: 36030188.
    • Pevner JL, Tanvetyanon T. Targeted therapy for lung cancer with paraneoplastic disseminated intravascular coagulation: A case report and pooled analysis. Clin Lung Cancer. 2022 Dec.23(8):e540-e544. Pubmedid: 36253272.
    • Darwin A, Skinner A, Reed DR, Tanvetyanon T. Immune-Related Toxicity Among Adolescent and Young Adult with Melanoma as Compared with the Elderly. J Adolesc Young Adult Oncol. 2022 Dec.11(6):550-555. Pubmedid: 35100046.
    • Tanvetyanon T. Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2022 Aug.387(6):571. Pubmedid: 35947717.
    • Robinson LA, Tanvetyanon T, Grubbs D, Robinson NA, Pierce CM, McCarthy K, Garcia-Getting R, Patel S. Preoperative nutrition-enhanced recovery after surgery protocol for thoracic neoplasms. J Thorac Cardiovasc Surg. 2021 Sep.162(3):710-720.e1. Pubmedid: 32713631.
    • Baby S, Khalil F, Tanvetyanon T. Frontline pembrolizumab for the treatment of RET-rearranged non-small cell lung cancer: A case report. Cancer Treat Res Commun. 2021 Jun.28:100423. Pubmedid: 34166867.
    • Rubiera-Pebe R, Hicks JK, Tanvetyanon T. Efficacy of tyrosine kinase inhibitors against lung cancer with EGFR exon 18 deletion: Case report and pooled analysis. Cancer Treat Res Commun. 2021 Jun.28:100407. Pubmedid: 34090219.
    • Maller B, Simmons VN, Byrne MM, Tanvetyanon T. Characteristics and Outcomes of Lung Cancer Screening Among Individuals With or Without Cancer History. Clin Lung Cancer. 2021 Jul.22(4):e629-e636. Pubmedid: 33441268.
    • Robinson LA, Babacan NA, Tanvetyanon T, Henderson-Jackson E, Bui MM, Druta M. Results of treating primary pulmonary sarcomas and pulmonary carcinosarcomas. J Thorac Cardiovasc Surg. 2021 Jul.162(1):274-284. Pubmedid: 32711968.
    • Kommalapati A, Tanvetyanon T. Epigenetic modulation of immunotherapy cofactors to enhance tumor response in lung cancer. Hum Vaccin Immunother. 2021 Jan.17(1):51-54. Pubmedid: 32460615. Pmcid: PMC7872084.
    • Darwin A, Rose T, Tandon A, Tanvetyanon T. Development of Bronchopleural Fistula After Durvalumab Consolidation for Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2021 Jan.22(1):e18-e24. Pubmedid: 32828661.
    • Perez BA, Kim S, Wang M, Karimi AM, Powell C, Li J, Dilling TJ, Chiappori A, Latifi K, Rose T, Lannon A, MacMillan G, Saller J, Grass GD, Rosenberg S, Gray J, Haura E, Creelan B, Tanvetyanon T, Saltos A, Shafique M, Boyle TA, Schell MJ, Conejo-Garcia JR, Antonia SJ. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021 Feb.109(2):425-435. Pubmedid: 33002543. Pmcid: PMC8465780.
    • Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021 Aug.27(8):1410-1418. Pubmedid: 34385708. Pmcid: PMC8509078.
    • Babacan NA, Pina IB, Signorelli D, Prelaj A, Garassino MC, Tanvetyanon T. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis. Clin Lung Cancer. 2020 Sep.21(5):e456-e463. Pubmedid: 32265109.
    • Mohamed AZ, Khalil FK, Toloza EM, Tanvetyanon T. Metastasectomy for Isolated Right-Sided Thoracic Lymph Node Metastasis From Tubal Carcinoma. Am Surg. 2020 May.86(5):521-523. Pubmedid: 32684038.
    • Babacan NA, Tanvetyanon T. Superimposed Clostridium difficile Infection During Checkpoint Inhibitor Immunotherapy-induced Colitis. J Immunother. 2019 Nov.42(9):350-353. Pubmedid: 31107370.
    • Gray JE, Saltos AN, Tanvetyanon T, Haura EB, Creelan BC, Antonia SJ, Shafique M, Zheng H, Dai W, Saller JJ, Chen Z, Tchekmedyian N, Goas K, Thapa R, Boyle TA, Chen DT, Beg AA. Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 Nov.25(22):6623-6632. Pubmedid: 31409616. Pmcid: PMC7234799.
    • Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creelan BC, Thapa R, Chen DT, Simon GR, Bepler G, Gabrilovich DI, Antonia SJ. Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. Cancer Immunol Immun. 2019 Mar.68(3):517-527. Pubmedid: 30591959. Pmcid: PMC6426813.
    • Shafique M, Tanvetyanon T. Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer. Expert Opin Biol Ther. 2019 Mar.19(3):225-232. Pubmedid: 30657338.
    • Hyland KA, Small BJ, Gray J, Chiappori A, Creelan B, Tanvetyanon T, Nelson AM, Cessna-Palas J, Jim HSL, Jacobsen PB. Loneliness as a mediator of the relationship of social cognitive variables with depressive symptoms and quality of life in lung cancer patients beginning treatment. Psychooncology. 2019 Jun.28(6):1234-1242. Pubmedid: 30932275.
    • Creelan BC, Gray JE, Tanvetyanon T, Chiappori AA, Yoshida T, Schell MJ, Antonia SJ, Haura EB. Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance. Brit J Cancer. 2019 Apr.120(8):791-796. Pubmedid: 30880334. Pmcid: PMC6474279.
    • Maller B, Kaszuba F, Tanvetyanon T. Complete Tumor Response of Tracheal Squamous Cell Carcinoma After Treatment With Pembrolizumab. Ann Thorac Surg. 2019 Apr.107(4):e273-e274. Pubmedid: 30326234.
    • Chatwal MS, Tanvetyanon T. Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?. Transl Lung Cancer Res. 2018 Sep.7(Suppl 3):S208-S210. Pubmedid: 30393603. Pmcid: PMC6193911.
    • Robinson LA, Tanvetyanon T, Grubbs D, Antonia S, Creelan B, Fontaine J, Toloza E, Keenan R, Dilling T, Stevens CW, Sommers KE, Vrionis F. Reply to Dickhoff et al. from authors of 'Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer'. Lung Cancer. 2018 Oct.124:322-323. Pubmedid: 30193907.
    • Maller B, Peguero E, Tanvetyanon T. Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma. J Immunother. 2018 Nov.41(9):411-412. Pubmedid: 29742520.
    • Tanvetyanon T, Keenan RJ. Recovery of lung function after segmentectomy versus lobectomy for early-stage lung cancer. J Thorac Dis. 2018 Jul.10(Suppl 18):S2144-S2146. Pubmedid: 30123544. Pmcid: PMC6072929.
    • Gray JE, Chiappori A, Williams CC, Tanvetyanon T, Haura EB, Creelan BC, Kim J, Boyle TA, Pinder-Schenck M, Khalil F, Altiok S, Devane R, Noyes D, Mediavilla-Varela M, Smilee R, Hopewell EL, Kelley L, Antonia SJ. A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. Cancer Immunol Immun. 2018 Dec.67(12):1853-1862. Pubmedid: 30209589. Pmcid: PMC6244998.
    • Robinson LA, Tanvetyanon T, Grubbs D, Antonia S, Creelan B, Fontaine J, Toloza E, Keenan R, Dilling T, Stevens CW, Sommers KE, Vrionis F. Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer. Lung Cancer. 2018 Aug.122:206-213. Pubmedid: 30032833.
    • Chatwal MS, Tanvetyanon T. Malignant mesothelioma clinical trial combines immunotherapy drugs. Immunotherapy. 2018 Apr.10(5):341-344. Pubmedid: 29473471.
    • Kass KS, Velez-Cubian FO, Zhang WW, Toosi K, Tanvetyanon T, Rodriguez KL, Thau MR, Garrett JR, Moodie CC, Fontaine JP, Toloza EM. Effect of advanced age on peri-operative outcomes after robotic-assisted pulmonary lobectomy: Retrospective analysis of 287 consecutive cases. Geriatr Oncol. 2017 Mar.8(2):102-107. Pubmedid: 28041970.
    • Tanvetyanon T, Gray JE, Antonia SJ. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?. Expert Opin Biol Ther. 2017 Mar.17(3):305-312. Pubmedid: 28064556.
    • Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017 Aug.10:4239-4250. Pubmedid: 28919776. Pmcid: PMC5587199.
    • Tanvetyanon T, Creelan BC, Antonia SJ. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. Expert Rev Anticancer Ther. 2016 Sep.16(9):903-910. Pubmedid: 27488231.
    • Mifsud MJ, Tanvetyanon T, Mccaffrey JC, Otto KJ, Padhya TA, Kish J, Trotti AM, Harrison LB, Caudell JJ. Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas. Head Neck. 2016 Nov.38(11):1628-1633. Pubmedid: 27098984.
    • Shields PG, Herbst RS, Arenberg D, Benowitz NL, Bierut L, Luckart JB, Cinciripini P, Collins B, David S, Davis J, Hitsman B, Hyland A, Lang M, Leischow S, Park ER, Purcell WT, Selzle J, Silber A, Spencer S, Tanvetyanon T, Tiep B, Tindle HA, Tucker-Seeley R, Urbanic J, Hooper MW, Weksler B, Whitlock CW, Wood DE, Burns J, Scavone J. Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2016 Nov.14(11):1430-1468. Pubmedid: 27799513.
    • Tanvetyanon T, Fisher K, Caudell J, Otto K, Padhya T, Trotti A. Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients. Head Neck. 2016 Jun.38(6):863-870. Pubmedid: 26340707.
    • Robinson LA, Tanvetyanon T, Springett G, Fontaine J, Toloza E, Hodul P, Pimiento JM, Malafa M. Pulmonary metastasectomy for suspected pancreaticobiliary cancer. J Thorac Cardiovasc Surg. 2016 Jul.152(1):75-82. Pubmedid: 27050555.
    • Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb.27(2):318-323. Pubmedid: 26598548. Pmcid: PMC4722891.
    • Tanvetyanon T, Boyle TA. Clinical implications of genetic heterogeneity in multifocal pulmonary adenocarcinomas. J Thorac Dis. 2016 Dec.8(12):E1734-E1738. Pubmedid: 28149626. Pmcid: PMC5227290.
    • Glover JR, Velez-Cubian FO, Zhang WW, Toosi K, Tanvetyanon T, Ng EP, Moodie CC, Garrett JR, Fontaine JP, Toloza EM. Effect of gender on perioperative outcomes after robotic-assisted pulmonary lobectomy. J Thorac Dis. 2016 Dec.8(12):3614-3624. Pubmedid: 28149556. Pmcid: PMC5227215.
    • Tanvetyanon T, Padhya T, McCaffrey J, Kish JA, Deconti RC, Trotti A, Rao NG. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2015 Jun.37(6):840-845. Pubmedid: 24623654.
    • Jacobsen PB, Lee JH, Fulp W, Siegel EM, Shibata D, Laronga C, Gray J, Tanvetyanon T, Schreiber F, Brown R, Levine R, Cartwright T, Abesada-Terk G, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Malafa M. Florida Initiative for Quality Cancer Care: Changes in Psychosocial Quality of Care Indicators Over a 3-Year Interval. J Oncol Pract. 2015 Jun.11(1):e103-e109. Pubmedid: 25352389. Pmcid: PMC4582141.
    • Tanvetyanon T, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Malafa M, Jacobsen PB. Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care. J Oncol Pract. 2015 Jul.11(4):332-337. Pubmedid: 25991639.
    • Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2015 Apr.51(4):376-382. Pubmedid: 25593015. Pmcid: PMC4459134.
    • Dilling TJ, Extermann M, Kim J, Thompson LM, Yue B, Stevens CW, Antonia S, Gray J, Williams C, Haura E, Pinder-Schenck M, Tanvetyanon T, Kim S, Chiappori A. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Nov.90(4):828-833. Pubmedid: 25216856.
    • Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience. Ann Surg Oncol. 2014 May.21(5):1480-1486. Pubmedid: 24158467.
    • Rodriguez K, Velez-Cubian F, Zhang WW, Tanvetyanon T, Thau M, Moodie C, Garrett J, Fontaine JP, Robinson L, Toloza E. Effects of pulmonary function and of smoking history on perioperative outcomes after robotic-assisted pulmonary lobectomy: retrospective analysis of 201 consecutive patients. Chest. 2014 Mar.145(3 Suppl):48A. Pubmedid: 24638644.
    • Gray J, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenk M, Kish JA, Kreahling JM, Lush RM, Neuger AM, Tetteh LF, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res. 2014 Mar.20(6):1644-1655. Pubmedid: 24429877. Pmcid: PMC4051132.
    • Rao NG, Han G, Greene JN, Tanvetyanon T, Kish JA, De Conti RC, Chuong MD, Shridhar R, Biagioli MC, Caudell JJ, Trotti AM. Effect of prophylactic fluconazole on oral mucositis and candidiasis during radiation therapy for head-and-neck cancer. Pract Radiat Oncol. 2014 Mar.3(3):229-233. Pubmedid: 24674369.
    • Tanvetyanon T, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Malafa M, Jacobsen PB. Changes in the care of non-small-cell lung cancer after audit and feedback: the Florida initiative for quality cancer care. J Oncol Pract. 2014 Jul.10(4):e247-e254. Pubmedid: 24737876.
    • Tanvetyanon T, Creelan BC, Chiappori AA. Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer. Cancer Control. 2014 Jan.21(1):32-39. Pubmedid: 24357739.
    • Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A. Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother. 2013 Oct.36(8):442-450. Pubmedid: 23994887. Pmcid: PMC3846277.
    • Kumar V, Nath K, Berman CG, Kim J, Tanvetyanon T, Chiappori AA, Gatenby RA, Gillies RJ, Eikman EA. Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med. 2013 Mar.38(3):175-182. Pubmedid: 23354032. Pmcid: PMC3578161.
    • Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul.31(19):2404-2412. Pubmedid: 23690416. Pmcid: PMC3691357.
    • May JT, Rao N, Sabater RD, Boutrid H, Caudell JJ, Merchant F, Han G, Padhya TA, McCaffrey JC, Tanvetyanon T, Deconti R, Kish J, McCaffrey TV, Trotti A. Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma. Head Neck. 2013 Dec.35(12):1796-1800. Pubmedid: 23468387.
    • Tanvetyanon T, Finley DJ, Fabian T, Riquet M, Voltolini L, Kocaturk C, Fulp WJ, Cerfolio RJ, Park BJ, Robinson LA. Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data. Ann Oncol. 2013 Apr.24(4):889-894. Pubmedid: 23136230.
    • Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Ne. 2012 Nov.10(11):1391-1398. Pubmedid: 23138167. Pmcid: PMC5726232.
    • Salah S, Tanvetyanon T, Abbasi S. Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. Lung Cancer. 2012 Jan.75(1):9-14. Pubmedid: 21864934.
    • Phillips KM, Jim HS, Small BJ, Tanvetyanon T, Roberts WS, Jacobsen PB. Effects of self-directed stress management training and home-based exercise on stress management skills in cancer patients receiving chemotherapy. Stress Health. 2012 Dec.28(5):368-375. Pubmedid: 22972771.
    • Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012 Apr.18(7):2056-2065. Pubmedid: 22241789. Pmcid: PMC5157199.
    • Tanvetyanon T, Corman M, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Bepler G, Siegel E, Shibata D, Malafa M, Jacobsen PB. Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in Florida. J Oncol Pract. 2011 Nov.7(6):e25-e31. Pubmedid: 22379428. Pmcid: PMC3219472.
    • Faul LA, Jim HS, Minton S, Fishman M, Tanvetyanon T, Jacobsen PB. Relationship of exercise to quality of life in cancer patients beginning chemotherapy. J Pain Symptom Manag. 2011 May.41(5):859-869. Pubmedid: 21330097. Pmcid: PMC3779914.
    • Bepler G, Dilling TJ, Wagner H, Hazelton T, Williams C, Chen DT, Greenberg H, Walsh F, Simon G, Tanvetyanon T, Chiappori A, Haura E, Stevens C. Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2011 Mar.6(3):553-558. Pubmedid: 21289520. Pmcid: PMC3839293.
    • Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar.28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.
    • Tanvetyanon T, Robinson L, Sommers KE, Haura E, Kim J, Altiok S, Bepler G. Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers. J Thorac Oncol. 2010 Jul.5(7):1018-1024. Pubmedid: 20453687.
    • Tanvetyanon T. Quality-of-care indicators for non-small cell lung cancer. Cancer Control. 2009 Oct.16(4):335-341. Pubmedid: 19910920.
    • Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D, DeConti R, Trotti A. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 2009 Jul.135(7):687-692. Pubmedid: 19620591.
    • Tanvetyanon T, Qin D, Padhya T, Kapoor R, McCaffrey J, Trotti A. Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis. Am J Otolaryngol. 2009 Jan.30(1):38-43. Pubmedid: 19027511.
    • Tanvetyanon T, Murtagh R, Bepler G. Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab. J Thorac Oncol. 2009 Feb.4(2):268-269. Pubmedid: 19179909.
    • Tanvetyanon T, Padhya T, McCaffrey J, Zhu W, Boulware D, Deconti R, Trotti A. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol. 2009 Apr.27(12):1983-1991. Pubmedid: 19289616.
    • Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol. 2008 Oct.3(10):1112-1118. Pubmedid: 18827606. Pmcid: PMC2639211.
    • Tanvetyanon T, Eikman EA, Sommers E, Robinson L, Boulware D, Bepler G. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol. 2008 Oct.26(28):4610-4616. Pubmedid: 18824709.
    • Tanvetyanon T, Robinson L, Schell M, Strong V, Kapoor R, Coit D, BeplerG. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008 Mar.26(7):1142-1147. Pubmedid: 18309950.
    • Tanvetyanon T, Bepler G. Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands. Cancer. 2008 Jul.113(1):150-157. Pubmedid: 18429004.
    • Tanvetyanon T. Cetuximab in head and neck cancer. N Engl J Med. 2008 Dec.359(25):2725-2726. Pubmedid: 19102011.
    • Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007 Jul.25(19):2741-2746. Pubmedid: 17602079.
    • Tanvetyanon T, Soares H, Djulbegovic B, Jacobsen P, Bepler G. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol. 2007 Dec.2(12):1091-1097. Pubmedid: 18090580.
    • Tanvetyanon T. Understanding the uncommon thoracic tumors. Cancer Control. 2006 Oct.13(4):252-253. Pubmedid: 17075561.
    • Tanvetyanon T, Stiff P. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006 Jun.17(6):897-907. Pubmedid: 16547070.
    • Tanvetyanon T, Bepler G. Commentary: concomitant chemotherapy and radiation for limited stage small cell lung cancer and benefit of adding additional drug into chemotherapy regimen for advanced non-small cell lung cancer. Cancer Treat Rev. 2006 Dec.32(8):656-657. Pubmedid: 16979297.
    • Tanvetyanon T, Garrity ER, Albain KS. Acute lung injury associated with vinorelbine. J Clin Oncol. 2006 Apr.24(12):1952-1953. Pubmedid: 16622272.
    • Tanvetyanon T, Choudhury A. Severity, risk factors, and physician practices in the management of anemia during concurrent chemoradiation for head and neck carcinoma. Cancer. 2006 Apr.106(7):1554-1559. Pubmedid: 16518817.
    • Tanvetyanon T, Choudhury AM. Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliative Care. 2006.22(4):281-285. Pubmedid: 17263055.
    • Tanvetyanon T. Reply to the article "The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer" by K.P. Weinfurt et al. (Ann Oncol 2005; 16: 579-584). Ann Oncol. 2005 Oct.16(10):1712-1713. Pubmedid: 15972282.
    • Tanvetyanon T. Consideration before administering cytotoxic chemotherapy to the critically ill. Crit Care Med. 2005 Nov.33(11):2689-2691. Pubmedid: 16276203.
    • Tanvetyanon T, Clark J, Campbell S, Lo S. Neoadjuvant therapy: an emerging concept in oncology. South Med J. 2005 Mar.98(3):338-344. Pubmedid: 15813161.
    • Tanvetyanon T. Medical costs associated with chiropractic care. Arch Intern Med. 2005 Jun.165(11):1313-1314. Pubmedid: 15956016.
    • Tanvetyanon T. Treatment of localized lymphoma. N Engl J Med. 2005 Jun.352(23):2449-2451. Pubmedid: 15944432.
    • Tanvetyanon T, Elmishad AG, Carbone M. Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link?. Anticancer Res. 2005 Jan.25(1B):429-433. Pubmedid: 15816607.
    • Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005 Jan.103(2):237-241. Pubmedid: 15597384.
    • Tanvetyanon T, Stiff P. Recurrent steroid-responsive pancreatitis associated with myelodysplastic syndrome and transformations. Leuk Lymphoma. 2005 Jan.46(1):151-154. Pubmedid: 15621795.
    • Tanvetyanon T. Talking about death with dying children. N Engl J Med. 2005 Jan.352(1):91-92. Pubmedid: 15635780.
    • Tanvetyanon T. Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2005 Jan.97(1):70. Pubmedid: 15632382.
    • Tanvetyanon T, Hines E J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer. 2005 Apr.103(8):1756-1757. Pubmedid: 15751014.
    • Tanvetyanon T. Molecular prediction of recurrence of breast cancer. N Engl J Med. 2005 Apr.352(15):1605-1607. Pubmedid: 15832454.
    • Tanvetyanon T, Toor A, Stiff P. Post-transplant air-leak syndrome. Br J Haematol. 2004 Sep.126(6):758-758. Pubmedid: 15352978.
    • Nand S, Tanvetyanon T. Proton pump inhibitors and iron deficiency: is the connection real?. South Med J. 2004 Sep.97(9):799. Pubmedid: 15455957.
    • Tanvetyanon T. Arterial thrombosis in systemic lupus erythematosus. N Engl J Med. 2004 Oct.351(18):1910-1911. Pubmedid: 15515221.
    • Tanvetyanon T. Which patient with a do-not-intubate order is a candidate for noninvasive ventilation?. Crit Care Med. 2004 Oct.32(10):2148-2150. Pubmedid: 15483429.
    • Tanvetyanon T, Stiff P. Second allogeneic transplantation using a reduced-intensity preparative regimen for relapsed myelofibrosis. Am J Hematol. 2004 Oct.77(2):204-205. Pubmedid: 15389913.
    • Tanvetyanon T, Nand S. Pancytopenia in hereditary haemorrhagic telangiectasia. Brit J Haematol. 2004 Nov.127(4):371. Pubmedid: 15521911.
    • Tanvetyanon T. Treatment of von Willebrand's Disease. N Engl J Med. 2004 Nov.351(22):2345-2346. Pubmedid: 15570685.
    • Tanvetyanon T. Re: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol. 2004 Nov.172(5 Pt 1):2082. Pubmedid: 15540794.
    • Tanvetyanon T, Nand S. Herpes zoster during treatment with arsenic trioxide. Ann Hematol. 2004 Mar.83(3):198-200. Pubmedid: 15064871.
    • Tanvetyanon T. Screening for primary human immunodeficiency virus infection. Arch Intern Med. 2004 Mar.164(6):680-680. Pubmedid: 15037504.
    • Tanvetyanon T, Choudhury A. Hypocalcemia and azotemia associated with zoledronic acid and interferon alfa. Ann Pharmacother. 2004 Mar.38(3):418-421. Pubmedid: 14970365.
    • Tanvetyanon T. HER-2 and fluorescent in situ hybridization to evaluate breast cancer. Jama. 2004 Jul.292(3):328. Pubmedid: 15265845.
    • Tanvetyanon T. Adjuvant treatment of breast cancer with exemestane. N Engl J Med. 2004 Jul.351(1):100-102. Pubmedid: 15237463.
    • Tanvetyanon T. Telephone psychotherapy and care management for depression. Jama. 2004 Dec.292(22):2720. Pubmedid: 15585725.
    • Tanvetyanon T, Ratanatharathorn V, Leopairat J. Mucoepidermoid carcinoma of the lung presenting as a cavitary lesion. J Med Assoc Thai. 2004 Aug.87(8):988-991. Pubmedid: 15471307.
    • Tanvetyanon T, Choudhury A. Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade. J Urol. 2004 Apr.171(4):1627. Pubmedid: 15017238.
    • Tanvetyanon T. Is hypocalcemia during therapy with zoledronic acid or other bisphosphonates beneficial to cancer patients?. Med Hypotheses. 2004.63(4):764-765. Pubmedid: 15325030.
    • Tanvetyanon T, Stadtmauer EA, Kerson LA. Concurrent administration of interferon alfa-2b and beta-1a. Ann Pharmacother. 2003 Jan.37(1):77-79. Pubmedid: 12503938.
    • Tanvetyanon T, Leighton J. Life-sustaining treatments in patients who died of chronic congestive heart failure compared with metastatic cancer. Crit Care Med. 2003 Jan.31(1):60-64. Pubmedid: 12544994.
    • Tanvetyanon T, Tapaneeyakorn J. Octreotide for bleeding as a result of hepatocellular carcinoma invasion of the gastrointestinal tract. J Gastroenterol Hepatol. 2003 Feb.18(2):231-232. Pubmedid: 12542614.
    • Tanvetyanon T, Nand S. Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing. Ann Pharmacother. 2003 Dec.37(12):1818-1820. Pubmedid: 14632593.
    • Sirisinha T, Ratanatharathorn V, Jirajarus M, Sirilerttrakul S, Silpakit C, Sirachainan E, Tanvetyanon T. The European Organization for Research and Treatment of Cancer quality of life questionnaire: translation and reliability study of the Thai version. J Med Assoc Thai. 2002 Nov.85(11):1210-1219. Pubmedid: 12546319.
    • Tanvetyanon T, Walkenstein M, Marra A. Inaccurate glucose determination by fingerstick in a patient with peripheral arterial disease. Ann Intern Med. 2002 Nov.137(9):W1. Pubmedid: 12416976.
    • Tanvetyanon T, Leighton J. Severe anemia and marrow plasmacytosis as presentation of Sjögren's syndrome. Am J Hematol. 2002 Mar.69(3):233. Pubmedid: 11891816.
    • Tanvetyanon T, Dissin J, Selcer U. Hyperthermia and chronic pancerebellar syndrome after cocaine abuse. Arch Intern Med. 2001 Feb.161(4):608-610. Pubmedid: 11252123.
    • Tanvetyanon T, Cohn J. Eligibility for outpatient treatment with low-molecular-weight heparin in venous thromboembolism. Arch Intern Med. 2000 Mar.160(6):869-870. Pubmedid: 10737288.
  • Patient Comments

    Overall Satisfaction


    194 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey



    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor